A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus

Recruiting Early Phase 1 Interventional Study
Systemic Lupus Erythematosus (SLE)
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 65
Sex
Any
Trial phase
Early Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
34 (estimated)
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory systemic lupus erythematosus.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
1. Subjects voluntarily participate in clinical research. 2. Age 18-65 years. 3. Have been diagnosed of SLE at least 6 months before screening. 4. At screening, antinuclear antibody, and/or anti-dsDNA antibody, and/or anti-Sm antibody should be positive. 5. Fulfill relapsed/refractory SLE conditions…
Contacts

Qiubai Li, Professor

85726808

qiubaili@hust.edu.cn

CONTACT